Bioxcel therapeutics announces proposed public offering

New haven, conn., feb. 08, 2024 (globe newswire) -- bioxcel therapeutics, inc. (the “company”) (nasdaq: btai), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it has commenced an underwritten public offering of $60.0 million of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. in addition, the company expects to grant the underwriters a 30-day option to purchase up to $9.0 million of additional shares of common stock at the public offering price, less the underwriting discounts and commissions.
BTAI Ratings Summary
BTAI Quant Ranking